Latest news with #Libre
Daily Record
3 days ago
- Entertainment
- Daily Record
'I worked at Boots and this little known perfume may be the scent of summer'
For the perfume fans among us, summer always presents an opportunity to find a new scent. With so many bottles on the market, many of us go for ones that are well known. However, amongst the Marc Jacobs and Hugo Boss offerings that tend to be bestsellers at this time of year, there are a few alternative options amongst them that are worth giving a go. One of them is the newly launched Zadig, by Parisian fragrance house, Zadig & Voltaire, a 'floriental woody fragrance for women' that, despite being a new addition to the market, has already earned glowing praise from one perfume fanatic. Bethan Shufflebotham of the Manchester Evening News, who used to work on the health and beauty chain's perfume counter, spotted this light, creamy coloured perfume on a recent store visit and said she "didn't know whether to shout about it from the rooftops, or keep it a closely guarded secret." After she couldn't resist spritzing the perfume, which boasts a unique wing-inspired bottle, the former Boots employee shared her full thoughts which can be found just below. "The result is a warm, smoky and incredibly moreish scent you can't help but keep going back to. It's feminine but powerful and a little edgy, like those cool girls that pull off a leather jacket thrown over a silk slip dress. "When I look at my perfume collection, it is pretty vanilla heavy, which is perhaps why I was so drawn to Zadig. According to perfume experts on TikTok, fragrances with similar profiles will tend to be housed in a bottle of a similar colour, which is a hack that comes in super handy when shopping fragrances online, or if you don't want to smell every bottle in store to find something you like. "With that theory in mind, some alternatives may include the likes of YSL Libre, which also contains orange blossom and vanilla. Zadig also says their wing-inspired bottle is symbolic of freedom, with Libre translating to 'free' in French. " Burberry Goddess would be another great choice, boasting key notes of vanilla and lavender. And coincidentally, Amandine Clerc-Marie was involved in crafting this popular 2023 scent, too. Despite being new to the market, Zadig is already holding its own, and has gained popularity with fans of Alien, Flowerbomb and Fame. One said: 'I'm usually quite pernickety about sweet fragrances but this was not overpowering at all. In fact I was regularly complimented when wearing it. It's a bit more tart than YSL Black Opium but I quite like that.' 'This is one of the best perfumes I've smelt in a while,' said another. 'It has a gorgeous fragrance and lasts all day. Quite a few people have commented when I wear it, I absolutely love it.' A third penned: 'Absolutely loved this. Gorgeous bold smell and really did last all day from one squirt. Usually wear Flowerbomb and this is a good rival for similar scent, but this is the longest lasting I've ever found.' The fragrance is also vegan and made from 89% natural-origin ingredients, plus the bottle is refillable, making it more sustainable than some other bottles available. However, some shoppers weren't so keen on the wing design. 'I absolutely love the scent of this fragrance. At first it smells quite strong but becomes subtle quite quickly, however I could still smell it on me 5+ hours later. I'm not a big fan of the statement bottle, which is why it's lost a star from me.' While the scent profile has earned much praise, some wearers (as above) report it lasting five plus hours, others note that it fades more quickly. Beauty deal of the week Looking for last minute gift inspiration for dad ahead of Sunday, June 15. Then don't fret, as we have you covered, as no-one can go wrong with a new bottle of cologne, and we have spotted Versace's The Dreamer for him Eau de Toilette for 67 percent less at Superdrug. Hailed for being "underrated" and "truly unique", a large 100ml bottle of this fragrance has been dropped from £74 to £24, allowing you to make a huge saving of £50 and get in a thoughtful gift. Described as "warm" and "fresh", Versace's Dreamer is an aromatic fragrance that, while belonging to the cologne family, is said to boast a variety of notes that make it suitable for both men and women. The scent opens on vibrant notes of juniper, tarragon, and artemisia, before blending into heart notes of iris, lily and flax flowers to add a touch of softness. It then ends on a comforting base of tobacco blossom and amber, offering a smoky, luxurious finish. The transparent, clear fragrance itself is housed in an opulent glass bottle that has been embossed with the iconic medusa logo, representing the luxury aesthetic of the iconic fashion house. Versace's Dreamer EDT has managed to earn glowing reviews and a 4.6 rating from shoppers, with one saying: "Truly unique and dreamy fragrance. It's a great fragrance but it's underrated. Guys you have to try this one, it's great for all year round." And someone else wrote: "Not to be overlooked. This is a lesser known Versace men's fragrance but oh my it is gorgeous ! Hubby loved it and amazing value for money." Versace's The Dreamer For Him Eau de Toilette (100ml) can be bought for 67 percent less at Superdrug now. One shopper who usually wears Fame or Alien said: 'Upon spraying a bit onto a sample stick I was not expecting to be wowed at all. How wrong I was. It smelled amazing. "Very reminiscent of my beloved long time signature scent of Alien. So I doused myself in the stuff before leaving the store. Went home and straight onto Boots online. "Decided to order myself the biggest bottle as best value for money. It's also refillable which also scores big brownie points with me. I've worn it once since it arrived and received many compliments on my scent and I've told everyone about 'Zadig''. Finishing her own review, Bethan added: "I will be honest I'd never heard of the brand or the perfume itself until I happened by it accidentally. I am saving mine for special occasions so as not to overwear it. "My only niggle is that I don't think the scent lasts all day as I couldn't smell it after a few hours unlike Alien and Fame. So even though it was a perfume as opposed to an EDT I feel they need to work on the longevity of the wear somehow." Perfume fans looking to try out the little known Zadig & Voltaire - ZADIG Eau de Parfum (90ml) can buy it for £110 from Boots now.
Yahoo
4 days ago
- Business
- Yahoo
Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth
-- Truist Securities launched coverage on four diabetes technology companies, saying there is a long-term growth potential for continuous glucose monitors (CGM) and insulin pumps amid rising adoption in both type 1 and type 2 diabetes patients. The firm started Dexcom (NASDAQ:DXCM), Insulet (NASDAQ:PODD), and Beta Bionics with Buy ratings, while initiating Tandem Diabetes Care (NASDAQ:TNDM) at Hold. Truist already covers Medtronic's diabetes business, which it rates 'Hold.' Truist said the diabetes device sector is positioned for double-digit growth over the next several years, driven by expanding use in underpenetrated global markets and a shift toward more patient-centric care. Survey feedback from physicians suggested stronger adoption of pumps and CGMs in type 2 diabetes, particularly among patients using insulin. Among the large-cap names, the firm favored Dexcom and Insulet, citing strong profitability and leadership in the growing CGM and patch pump segments. While Truist said that Insulet's recent CEO change may introduce some near-term uncertainty, it said the company's growth trajectory remains intact. Dexcom, which has faced concerns following mid-2024 execution missteps and rising competition from Abbott's Libre system, still offers a favorable risk-reward, Truist said, pointing to a lower relative valuation and catalysts such as guideline updates and expanding reimbursement for type 2 diabetes. In the small-cap space, Truist preferred Beta Bionics over Tandem. It noted both firms face challenges in the slower-growing durable pump market but said Beta Bionics' iLet system has a potential ease-of-use advantage and a head start in transitioning to more profitable pharmacy distribution channels. Regarding potential volatility in shares of both Beta Bionics and Tandem, Truist said the broader diabetes device market remains one of the most attractive growth areas in medtech, supported by technology innovation, evolving reimbursement, and increased patient engagement. Related articles Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth Boeing Commercial Airplanes head meets Air India chairman after fatal 787 crash Forward Air stock surges on report PE firms express acquisition interest
Yahoo
24-05-2025
- Business
- Yahoo
Was Jim Cramer Right About Abbott Laboratories (ABT)?
We recently published a list of . In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 20, a caller asked whether to hold or buy more shares of Abbott Laboratories (NYSE:ABT), amid a pending lawsuit over baby formula. Cramer remained positive on the outlook but advised waiting for a lower entry. 'The outlook is fabulous. There is a lawsuit in July involving formula — its competitor Reckitt Benckiser lost a case. I think that this is not going to be a big deal. But it doesn't matter — people know what happened with J&J and they're scared. We're waiting till at least it gets to par or 100 to be able to buy more. But we believe in the company.' Abbott Laboratories delivered steady growth with a 28.54% gain, justifying his patient buy-on-dip approach. Abbott Laboratories (NYSE:ABT) is rebounding as its diversified healthcare products and diagnostics tools see renewed investor interest. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Discussing the stock's valuation, Cramer gave the following analysis in May this year: 'Okay, their forward PE shows that there's going to be a, pretty much of an earnings explosion. And I think a lot of that's going to be coming from Libre, which is their diabetes, they have the best diabetes device. It's cheaper than everybody's. Overall, ABT ranks 2nd on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
From Acquisition to Advantage: Abbott's Growth in Heart Care
Investment Thesis With 7% top-line growth and 8% bottom-line growth across the majority of its divisions, Abbott Labs reported a solid first-quarter performance. Due to the possibility of sustained high healthcare utilization in 2024, the company's growth is anticipated to continue in 2025. The Libre franchise, structural heart, and heart failure were the main drivers of the 13% annual growth in medical devices. Weak sales of COVID tests caused Diagnostics to drop 5%. Tariffs are predicted to have an annual impact of about $300 million, with an additional $500 million in 2026. Abbott anticipates further increases in its gross margin in 2027 as a result of optimizing its manufacturing footprint to reduce tariff exposure. The company's Volt pulsed field ablation device was approved by European regulators, which may help it take market share away from rivals. Abbott has used its mapping technology to defend its electrophysiology business, even though it was late to introduce its own PFA ablation catheters, falling behind Boston Scientific and Medtronic. Whether practitioners will leave Abbott or move to Volt is still up in the air. Competitive Overview Drugs: Regarding the drug industry, Abbott comes head to head with Pfizer, Novartis, and Johnson & Johnson. Much like Abbott, these rivals are focusing on the same therapeutic fields, like cardiovascular health and diabetes management, and are taking away parts of the Abbott market due to their advanced research potential and wide range of medicines. Medical Equipment: The medical devices division pits Abbott against Medtronic, Boston Scientific, and Stryker. These competitors produce devices that are relevant to cardiovascular devices, neuromodulation, and diabetes care, for example, Abbott's FreeStyle Libre, which is a glucose monitoring system. Competition is fueled by ongoing international patent disputes, the latest of which was with Medtronic regarding the cardiovascular devices technology, which led to legal and innovative pressures. Diagnostics: In the diagnostic field, Abbott is the one that dominates the market by a large margin, especially after its breakthrough COVID-19 testing kits. But Roche, Siemens Healthineers, and Thermo Fisher Scientific being fierce rivals make things a little tough for it, as all of them supply analog diagnostic tests and devices. A rivalry of this magnitude was seen across the pandemic period, as demand for effective and trusted testing processes increased, they had no choice but to keep coming up with new ideas. Food: The section related to food has Abbott contesting with Nestle, Danone, and Reckitt Benckiser. Such rivals are selling equivalent products like baby formula (e.g., Abbott's Similac vs. Nestle's NAN) and adult nutrition, catching consumer trust and shelf space in a highly brand-driven market. Investment Upsides The market is dominated by three or four competitors, including those in the following areas: immunoassays, coronary stents, venous closure, continuous glucose monitors, cardiac rhythm management devices, surgical heart valves, and nutrition. Abbott benefits from intangible assets that generate economic profits in these markets. One of Abbott's most lucrative divisions is the nutritional division, which holds a dominant position in a highly consolidated market valued at an estimated $35 billion globally. The company has created proprietary formulas of specialty infant formulas for infants with allergies and metabolic issues, as well as intangible assets like brand trust with pediatricians and new parents. Due to the rise in middle-class families and the resulting demand for adult and pediatric nutrition products, ambient markets, including emerging markets, present more promising long-term growth prospects. Abbott is able to enter new markets thanks to its powerful Similac and Ensure brands, which give it an edge when launching new formulations and line extensions. Known as branded generics, Abbott's well-established pharmaceutical product line primarily sells to pharmacies and doctors directly, functioning more like a consumer business than traditional branded medications. Abbott's primary advantages in this market are its reputation and brand recognition, which could shift in the long run as more emerging markets adopt the developed-nation tender system. The 2017 acquisition of St. Jude Medical by Abbott for $25 billion was a high game changer in the cardiovascular segment. As a leading company in vascular care, Abbott, which combines the St. Jude's strength in the areas of heart failure, arrhythmia, and structural heart devices, has increased its market share effectively. The company revealed that it held the No. 1 or No. 2 positions in the cardiovascular segment, which comprises a $30 billion market, resulting from the accomplishment of a considerable increase in market presence that is inherent to the above-mentioned situation. Moreover, a revenue boost was also experienced. In 2016, the cardiovascular sales of Abbott were $2.9 billion. After including St. Jude's $5.5 billion, the total sales for the year 2017 reached the fantastic figure of $10.7 billion. The organic growth was down by 2.9%, but this was due to the integration, which was, of course, a temporary effect. To continue the growth story, in 2018, the organic growth was at 10.1%, in 2019 it was at 7.3%. Thus, it can be said that the acquisition gave a solid push in the long run. Although the first year of the acquisition saw the profitability get hit, recently there has been a turnaround. The medical devices segment experienced a decrease in operating margin from 38% in 2016 to 13% in 2017 mainly because of the integration expenses tagging along. Nevertheless, it was on track again in 2018 with 18% operating margin and again in 2019 with a further increase to 20% operating margin, all this due to the $500 million in annual synergies attained by 2020. In summary, the acquisition facilitated the growth of Abbott by enhancing its market position, increasing the revenue, and after the initial challenges, the profitability in the cardiovascular segment improved. Abbott gains a great deal from legacy St. Jude's remarkable proficiency in heart failure, structural heart, and cardiac rhythm management. Specialized engineering knowledge, proficiency in navigating the regulatory pathway, and solid sales representative relationships with practitioners are examples of intangible assets in this segment. After being implanted inside the body, high-margin devices like pacemakers, cardiac resynchronization devices, spinal cord stimulators, and implantable cardioverter defibrillators benefit from high switching costs. The diagnostics segment exhibits switching costs, which are common in the life sciences market, and deviates slightly from the other divisions. Abbott uses intellectual property to protect some degree of product differentiation and to keep rivals out of the device and diagnostic markets. In the field of medical technology, patents are not infallible, though, because rivals may develop a different approach to a comparable solution. Although Abbott's businesses show signs of moatiness, there is less confidence in the company's long-term ability to foster and revitalize innovation. The business is more likely to follow Boston Scientific and Medtronic to market than to forge its own route. Intrinsic Valuation ABT's shares are modestly overvalued. Despite the COVID-19 crisis, Abbott's balance sheet has remained a solid pillar of strength. Leverage was increased by the acquisitions of Alere and St. Jude Medical, and the company's debt to EBITDA ratio has remained at about 1.5 times, suggesting that it can produce $6 billion to $7 billion in free cash flow annually. Abbott has been able to support large dividend increases and make more tuck-in acquisitions thanks to the Covid-19 windfall. Over the next few years, the company's estimated interest coverage of EBITDA/interest will increase to 20 times. Revenue from non-COVID diagnostics is anticipated to remain stable in 2025, with Abbott largely regaining market share in infant formula. The established pharmaceuticals business will stabilize with mid-single-digit growth, and procedure volume will continue to be strong. There will be a moderate uptake of Abbott's recent new product launches, such as the Amplatzer Amulet for left atrial appendage closure. Throughout the explicit forecast period, the company can increase its operating margin by about 230 basis points, mostly as a result of new products and a closing operating margin gap between Abbott and its main rivals. Notable Guru Holdings Jeremy Grantham (Trades, Portfolio) (Trades, Portfolio) 48 Abbott Laboratories transactions (GMO data-href="" style=""/> Ken Fisher (Trades, Portfolio) (Trades, Portfolio) 48 Abbott Laboratories transactions (Fisher data-href="" style=""/> Jeremy Grantham (Trades, Portfolio) of GMO LLC, knowing for his long term investment philosophy had been buying shares since 2023 and ABT has awarded him with commendable returns as his average buying price stands at $53.9. Investment Downsides The potential commercial success of Abbott's Libre franchise, which includes expansions to new patient populations, and persistent problems with its left ventricular assist devices are among the risks the company faces. Additionally, the business is susceptible to disruptive innovation from competitors, especially in its diagnostic and medical device divisions. Abbott faced a significant formula recall in the US as a result of Cronobacter poisoning cases, despite efforts to safeguard itself against recalls. There is still a chance of product quality problems or recalls, which could harm the company's reputations and connections with healthcare providers. Abbott is under more pressure to lower prices due to tighter budgets and more competitive tenders in China. The US Food and Drug Administration and regulatory bodies abroad also keep an eye on Abbott's operations, which may cause delays in product approvals or manufacturing. Portfolio Management While Abbott has acquired some noteworthy companies, like Knoll and St. Jude Medical, it has also acquired less noteworthy companies, like Advanced Medical Optics and the Guidant stent division. Given that the majority of its cardiovascular portfolio was acquired through mergers and acquisitions, the company's capacity to foster innovation after acquiring assets is a cause for concern. Given Abbott's history of dividend increases and dividend payments, the level of shareholder distributions is appropriate. However, these buybacks were somewhat dilutive because the company spent $1.5 billion on repurchasing shares in 2020 and 2021, right when demand for diagnostics related to the pandemic was booming. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-05-2025
- Business
- Yahoo
Abbott Laboratories (ABT)'s Libre Linked to Fewer Heart Hospitalizations in Diabetes
Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a notable decrease in hospitalizations for heart-related complications among people with diabetes. For the first time, the data demonstrate that CGM technology can reduce the severity of cardiovascular issues in individuals with Type 1 diabetes, regardless of their history with low blood sugar or previous heart-related hospital stays. The studies also showed a similar drop in heart-related hospital admissions for people with Type 2 diabetes who use the Libre biowearable device while on insulin. In its announcement, Abbott Laboratories (NYSE:ABT) highlighted that diabetes affects 589 million people globally. Managing blood sugar and preventing complications like heart disease are critical challenges for those living with the condition. Ramzi Ajjan, M.D., professor of Metabolic Medicine at Leeds University and Leeds Teaching Hospitals Trust, made the following comment on this development: "I regularly treat people with diabetes who have problems with their blood vessels, resulting in heart attacks, strokes and amputations. These blood vessel problems, known collectively as cardiovascular disease, remain the main causes of ill health in people with diabetes. I am very excited to see data that show a significant reduction in cardiovascular disease-related hospital admissions. It's great to see the clear, positive impact of FreeStyle Libre technology on cardiovascular outcomes, making diabetes management more effective and improving the health of our patients." Abbott Laboratories (NYSE:ABT)'s breakthrough in diabetes is well-received by analysts, its dividend policy has also garnered investors' attention over the years. The company is a Dividend King with 53 consecutive years of dividend growth under its belt. Currently, it pays a quarterly dividend of $0.59 per share and has a dividend yield of 1.75%, as of May 18. The stock surged by over 30.6% in the past 12 months. While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
